Friday, 18 Aug 2017

You are here

Romosuzumab Outperforms Teriparatide in Post-Bisphosphonate Osteoporosis

The STRUCTURE trial results have been reported in Lancet and have shown that after 12 months of therapy, romosozumab (ROMO) had superior gains in bone mineral density (BMD) compared to teriparatide (TER) in women with postmenopausal osteoporosis who have previously taken bisphosphonate therapy.

This phase 3 trial enrolled women (aged ≥55 to ≤90 years) with postmenopausal osteoporosis who had previously received oral bisphosphonate therapy for > 3 years and had a BMD T score of −2·5 or lower at the total hip, femoral neck, or lumbar spine; and a history of fracture. Patients were treated withe either ROMO (210 mg once monthly) or subcutaneous TER (20 μg once daily) and the primary endpoint was the percentage change in BMD at 12 months.

A total of 436 patients were randomized. At 12 months, the mean change in hip BMD was 2·6% (95% CI 2·2 to 3·0) for ROMO and −0·6% (−1·0 to −0·2) for TER treated patients (p<0·0001).

The frequency of adverse events and serious AEs were balanced between treatment groups. The most frequently reported adverse events were nasopharyngitis, hypercalcaemia and arthralgia. There were six (3%) patients in the romosozumab group compared with 12 (6%) in the teriparatide group with adverse events leading to drug withdrawal.

Thus for those requiring a bone-forming agent after bisphosphonates, it appears that the use of the anti-sclerostin drug, romosozumabm, may lead to better gains in hip BMD compared to teriparatide.

To date, more than 11,000 patients have received ROMO in clinical trials. Yet last month the FDA issued a complete response letter to the  manufacturers over concerns about cardiovascular events in subsequent trials. FDA has asked UCB and Amgen to provide additional data on the safety and efficacy of ROMO in their phase 3 active-comparator ARCH study and BRIDGE study.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Bad Knees Through the Ages

The average American today is twice as likely to be diagnosed with knee osteoarthritis as in the years before World War II, Harvard scientists say. And the reasons are less clear than you might think.

Based on a study of more than 2,000 skeletons from cadaveric and archaeological collections across the United States, a Harvard report is the first to definitively show that knee osteoarthritis prevalence has dramatically increased in recent decades.

Osteoporosis Care for RA Patients Found Suboptimal, Declining

Fewer than half of rheumatoid arthritis (RA) patients at a risk of fracture sufficient to warrant guideline-recommended osteoporosis treatment received appropriate care, according to a large study of U.S. osteoarthritis (OA) and RA patients.

Kids with Crohn's have Profound MSK Deficits - but No Increase in Fractures

Crohn’s disease (CD), a chronic inflammatory condition of the gastrointestinal tract, is also known for its propensity to affect the musculoskeletal system. Extraintestinal complications of CD include inflammatory polyarthritis, loss of muscle mass, growth retardation and vertebral compression fractures. Some of these are direct results of inflammation or indirect effects of malnutrition.

Joint Pain Linked to Increasing Temperature, Not Rainfall

Every rheumatologist knows and every rheumatic patient woes about the havoc weather inflicts on joint pains. Yet, research on this issue has seldom confirmed these impressions.  A novel new look has shown by linking online search terms with published weather conditions that increasing climate temperatures increased rates of hip and knee pain (searches), while precipitation had no effect.

Denosumab Increases Trabecular Bone

Bone mineral density (BMD) measurement vie DEXA scan commonly used to assess bone density and fracture risk in postmenopausal osteoporosis provides us with approximate assessment of bone health while lacking sensitivity in vertebral fracture risk prediction. Newer techniques, such as the trabecular bone score (TBS), provide better insight into bone microarchitecture - an important factor for fragility fracture.